Loading...
ADVENZYMES logo

Advanced Enzyme Technologies LimitedNSEI:ADVENZYMES 株式レポート

時価総額 ₹43.2b
株価
₹386.20
₹370
4.4% 割高 内在価値ディスカウント
1Y33.8%
7D5.7%
1D
ポートフォリオ価値
​
表示

Advanced Enzyme Technologies Limited

NSEI:ADVENZYMES 株式レポート

時価総額：₹43.2b

Advanced Enzyme Technologies（ADVENZYMES）株式概要

アドバンスド・エンザイム・テクノロジーズ・リミテッドは、その子会社とともに、インド、ヨーロッパ、米国、アジア、そして国際的に酵素とプロバイオティクスの研究、開発、製造、販売に従事している。 詳細

ADVENZYMES ファンダメンタル分析
スノーフレーク・スコア
評価1/6
将来の成長2/6
過去の実績5/6
財務の健全性6/6
配当金3/6

報酬

収益は年間10.03%増加すると予測されています

過去1年間で収益は28.7%増加しました

リスク分析

リスクチェックの結果、ADVENZYMES 、リスクは検出されなかった。

ADVENZYMES Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Advanced Enzyme Technologies Limited 競合他社

価格と性能

株価の高値、安値、推移の概要Advanced Enzyme Technologies
過去の株価
現在の株価₹386.20
52週高値₹419.00
52週安値₹251.95
ベータ0.69
1ヶ月の変化29.75%
3ヶ月変化23.41%
1年変化33.77%
3年間の変化39.95%
5年間の変化-18.46%
IPOからの変化40.42%

最新ニュース

ナラティブの更新 • May 12

ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns

Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.
ナラティブの更新 • Apr 19

ADVENZYMES: Steady Risk And Margins Will Support Future Upside

Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.
ナラティブの更新 • Apr 05

ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside

Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.

Recent updates

ナラティブの更新 • May 12

ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns

Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.
ナラティブの更新 • Apr 19

ADVENZYMES: Steady Risk And Margins Will Support Future Upside

Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.
ナラティブの更新 • Apr 05

ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside

Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.
ナラティブの更新 • Mar 21

ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside

Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.
ナラティブの更新 • Mar 06

ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside

Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.
ナラティブの更新 • Feb 20

ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside

Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
ナラティブの更新 • Feb 05

ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares

Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
分析記事 • Jan 31

Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up

There wouldn't be many who think Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) price-to-earnings (or "P/E...
新しいナラティブ • Aug 17

Preventive Health And Green Chemistry Will Expand Future Markets

Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.
分析記事 • Aug 04

Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...
分析記事 • Jun 27

Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20

The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...
分析記事 • Jun 12

Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20

The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...
分析記事 • Mar 25

Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Aug 20

After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar

Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) shareholders have had their patience rewarded with a 26% share...
分析記事 • Jul 19

We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now

Key Insights Advanced Enzyme Technologies' Annual General Meeting to take place on 25th of July Salary of ₹6.69m is...
分析記事 • Jul 13

Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00

The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.00...
分析記事 • Apr 08

Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business

What are the early trends we should look for to identify a stock that could multiply in value over the long term...
分析記事 • Sep 23

Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
分析記事 • Feb 03

Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...
分析記事 • Aug 11

Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...
分析記事 • May 13

With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
分析記事 • Mar 28

Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...
分析記事 • Mar 13

The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?

When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a...
分析記事 • Feb 21

Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)

We note that a Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) insider, Madhusudan Soni, recently sold ₹5.7m...

株主還元

ADVENZYMESIN ChemicalsIN 市場
7D5.7%0.1%-0.2%
1Y33.8%-2.7%0.02%

業界別リターン: ADVENZYMES過去 1 年間で-2.7 % の収益を上げたIndian Chemicals業界を上回りました。

リターン対市場: ADVENZYMES過去 1 年間で0 % の収益を上げたIndian市場を上回りました。

価格変動

Is ADVENZYMES's price volatile compared to industry and market?
ADVENZYMES volatility
ADVENZYMES Average Weekly Movement6.4%
Chemicals Industry Average Movement7.2%
Market Average Movement7.2%
10% most volatile stocks in IN Market10.1%
10% least volatile stocks in IN Market4.8%

安定した株価: ADVENZYMES 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: ADVENZYMESの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
1957338n/awww.advancedenzymes.com

アドバンスド・エンザイム・テクノロジーズ社は、その子会社とともに、インド、欧州、米国、アジア、および国際的な酵素およびプロバイオティクスの研究、開発、製造、販売に従事している。酵素とプロバイオティクスをベースとした栄養補助食品を、ヒトの健康管理、動物栄養、果物・野菜加工、製パン、醸造・製麦、でんぷん・穀物加工、たんぱく質改質、酵母加工、乳製品・チーズ加工、油脂加工、特殊用途、バイオ燃料、バイオ触媒向けに提供している。また、繊維、皮革、紙パルプ加工用の非食品加工用酵素や、洗剤、洗浄助剤も提供している。以前はアドバンスト・バイオケミカルズ社として知られていたが、2005年にアドバンスト・エンザイム・テクノロジーズ社に社名変更。アドバンスト・エンザイム・テクノロジーズ社は 1957 年に設立され、インドのテーンに本拠を置く。

Advanced Enzyme Technologies Limited 基礎のまとめ

Advanced Enzyme Technologies の収益と売上を時価総額と比較するとどうか。
ADVENZYMES 基礎統計学
時価総額₹43.23b
収益（TTM）₹1.69b
売上高(TTM)₹7.81b
25.6x
PER（株価収益率
5.5x
P/Sレシオ

ADVENZYMES は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ADVENZYMES 損益計算書（TTM）
収益₹7.81b
売上原価₹1.93b
売上総利益₹5.88b
その他の費用₹4.19b
収益₹1.69b

直近の収益報告

Mar 31, 2026

次回決算日

該当なし

一株当たり利益（EPS）15.07
グロス・マージン75.28%
純利益率21.61%
有利子負債／自己資本比率1.2%

ADVENZYMES の長期的なパフォーマンスは？

過去の実績と比較を見る

配当金

1.3%
現在の配当利回り
38%
配当性向

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/21 07:22
終値2026/05/21 00:00
収益2026/03/31
年間収益2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Advanced Enzyme Technologies Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4

アナリスト機関
Nandan ChakrabortyAxis Capital Limited
Abhishek NavalgundCentrum Broking Limited
null nullDBS Bank Ltd